A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma
Barry Paul, Michaela Liedtke, Jack Khouri, Robert M. Rifkin, Mitul D Gandhi, Andrew Kin, Moshe Levy, Rebecca Silbermann, Francesca Cottini, Douglas W. Sborov, Irwindeep Sandhu, Lyssa Villarreal, Michael Murphy, Lin Gu, Ann Chen, Nishanthan Rajakumaraswamy, Saad Z. Usmani
Abstract
Magrolimab is a monoclonal antibody that blocks CD47, a 'do not eat me' signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).